ArticleUrology annals
Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer.
Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.Prostate cancer and prostatic diseases · 2023Trial
- Article
- Utility of PSMA PET/CT for staging of favourable risk intermediate risk prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Non-invasive MRI-based assessment of reactive stromal grade in prostate cancer using diffusion kurtosis imaging and stretched-exponential model.BMC medical imaging · 2025Article
- Intralesional and perilesional radiomics strategy based on different machine learning for the prediction of international society of urological pathology grade group in prostate cancer.BMC medical imaging · 2025Article
- The value of synthetic magnetic resonance imaging in the diagnosis and assessment of prostate cancer aggressiveness.Quantitative imaging in medicine and surgery · 2024Article
- Risk subtyping and prognostic assessment of prostate cancer based on consensus genes.Communications biology · 2022Article
- Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis.Frontiers in medicine · 2022Article
- PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer underCancers · 2021Article
- Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer.Cancers · 2021Review
- The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.International journal of medical sciences · 2020Article
- PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA.Acta clinica Croatica · 2019Article
- Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA.Clinical proteomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim is to assess for a difference in the incidence of metastasis (IM) and prostate-specific antigen (PSA) levels at diagnosis in patients with Gleason score (GS) 3+4 versus 4+3 prostate cancer using a large veterans affairs database. SUBJECTS AND
methodsA retrospective review of 1402 medical records from 5 VA hospitals was conducted. The study period was from 2009 to 2014. Primary endpoints were IM and PSA levels at diagnosis. A secondary endpoint was overall survival. STATISTICAL ANALYSIS USED: Chi-square tests for categorical variables, Student's
resultsThere were 1050 patients with GS3+4 and 352 with GS4+3. There were no differences in sociodemographic and clinical characteristics of the study population. PSA at the time of diagnosis was significantly higher in the GS4+3 patients compared to GS3+4 (18.0 vs. 11.4, respectively;
conclusionsOur results indicate that patients with GS4+3 prostate cancers have higher PSA levels at diagnosis. GS4+3 is associated with 3-fold increased risk of IM at diagnosis than GS3+4 though the overall incidence is low. Further research is needed to assess whether GS4+3 patients need routine staging imaging investigations at the time of diagnosis similar to patients with higher Gleason scores (GS ≥8).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.